Effectiveness of a vaccine composed of heat-killed Candida albicans and a novel mucosal adjuvant, LT(R192G), against systemic candidiasis

Infection and Immunity

Volumn 67, Issue 2, 1999, Pages 826-833

  Cárdenas Freytag, Lucía ^a   Cheng, Elly ^a   Mayeux, Patricia ^a   Domer, Judith E ^a   Clements, John D ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANDIDA ALBICANS VACCINE; IMMUNOLOGICAL ADJUVANT; MUCOSAL ADJUVANT LT(R192G); UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CELLULAR IMMUNITY; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG EFFICACY; IMMUNIZATION; INTRANASAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL;

EID: 0344820782     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.67.2.826-833.1999     Document Type: Article

References (54)

1. Balish, E., J. Jensen, T. Warner, J. Brekke, and B. Leonard. 1993. Mucosal and disseminated candidiasis in gnotobiotic SCID mice. J. Med. Vet. Mycol. 31:143-154.
2. Banerjee, U., L. N. Mohapatra, and R. Kumar. 1985. Effect of immunization with formalin killed cells in complete Freund's adjuvant in experimental candidosis. Indian J. Med. Res. 81:454-458.
3. Bistoni, F., A. Vecchiarelli, E. Cenci, P. Puccetti, P. Marconi, and A. Cassone. 1986. Evidence for macrophage-mediated protection against lethal Candida albicans infection. Infect. Immun. 51:668-674.
4. Bromuro, C., R. La Valle, S. Sandini, F. Urbani, C. M. Ausiello, L. Morelli, C. Fe d'Ostiani, L. Romani, and A. Cassone. 1998. A 70-kilodalton recombinant heat shock protein of Candida albicans is highly immunogenic and enhances systemic murine candidiasis. Infect. Immun. 66:2154-2162.
5. + lymphocytes in resistance to mucosal candidiasis. Infect. Immun. 59:2447-2455.
6. Casadevall, A. 1995. Antibody immunity and invasive fungal infections. Infect. Immun. 63:4211-4218.
7. + lymphocytes in protective immunity to systemic Candida albicans infection in mice. Infect. Immun. 57:3581-3587.
8. Chong, C., M. Frieberg, and J. D. Clements. 1998. LT(R192G), a non-toxic mutant of the heat-labile enterotoxin of Escherichia coli elicits enhanced humoral and cellular immune responses associated with protection against lethal oral challenge with Salmonella spp. Vaccine 16:732-740.
9. Clements, J. D., and R. A. Finkelstein. 1979. Isolation and characterization of homogeneous heat-labile enterotoxins with high specific activity from Escherichia coli cultures. Infect. Immun. 24:760-769.
10. Clements, J. D., N. M. Hartzog, and F. L. Lyon. 1988. Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens. Vaccine 6:269-277.
11. Cohen, R., F. J. Roth, E. Delgado, D. G. Ahearn, and M. H. Kalser. 1969. Fungal flora of the normal human small and large intestine. N. Engl. J. Med. 280:638-641.
12. Cooper, M. G. 1972. Delayed-type hypersensitivity in the mouse. I. Induction and elicitation by Salmonella adelaide flagellin and its derivatives. Scand. J. Immunol. 1:167-178.
13. Costantino, P. J., K. M. Franklyn, N. F. Gare, and J. R. Warmington. 1994. Production of antibodies to antigens of Candida albicans in CBA/H mice. Infect. Immun. 62:1400-1405.
14. Crowle, A. J. 1975. Delayed hypersensitivity in the mouse. Adv. Immunol. 20: 197-264.
15. De Bernardis, F., M. Boccanera, D. Adriani, E. Spreghini, G. Santoni, and A. Cassone. 1997. Protective role of antimannan and anti-aspartyl proteinase antibodies in an experimental model of Candida albicans vaginitis in rats. Infect. Immun. 65:3399-3405.
16. Dickinson, B. L., and J. D. Clements. 1995. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect. Immun. 63:1617-1623.
17. Dickinson, B. L., and J. D. Clements. 1996. Use of Escherichia coli heat-labile enterotoxin as an oral adjuvant, p. 73-87. In H. Kiyono, P. L. Ogra. and J. R. McGhee (ed.). Mucosal vaccines. Academic Press. Inc., San Diego, Calif.
18. Domer, J. E., and R. F. Hector. 1987. Enhanced immune responses in mice treated with penicillin-tetracycline or trimethoprim-sulfamethoxazole when colonized intragastrically with Candida albicans. Antimicrob. Agents Chemother. 31:691-697.
19. Domer, J. E., and S. A. Moser. 1978. Experimental murine candidiasis: cell-mediated immunity after cutaneous challenge. Infect. Immun. 20:88-98.
20. Eckstein, M., Y. Barenholz, L. K. Bar, and E. Segal. 1997. Liposomes containing Candida albicans ribosomes as a prophylactic vaccine against disseminated candidiasis in mice. Vaccine 15:220-224.
21. Elson, C. 1996. Cholera toxin as a mucosal adjuvant, p. 59-72. In H. Kiyono, P. L. Ogra, and J. R. McGhee (ed.), Mucosal vaccines. Academic Press. Inc., San Diego, Calif.
22. Elson, C. O. 1989. Cholera toxin and its subunits as potential oral adjuvants, Immunol. Today 146:29-33.
23. Gallagher, S., S. E. Winston, S. A. Fullerr, and J. G. R. Hurrell. 1997. Immunoblotting and immunodetection, p. 10.8. In F. M. Ausubel, R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl (ed.), Current protocols in molecular biology. John Wiley & Sons, Inc., New York, N.Y.
24. Garner, R. E., U. Kuruganti, C. W. Czarniecki, H. H. Chiu, and J. E. Domer. 1989. In vivo immune responses to Candida albicans modified by treatment with recombinant murine gamma interferon. Infect. Immun. 57:1800-1808.
25. Giger, D. K., J. E. Domer, and J. T. McQuitty, Jr. 1978. Experimental murine candidiasis: pathological and immune responses to cutaneous inoculation with Candida albicans. Infect. Immun. 19:496-509.
26. Giger, D. K., J. E. Domer, S. A. Moser, and J. T. McQuitty, Jr. 1978. Experimental murine candidiasis: pathological and immune responses in T-lymphocyte-depleted mice. Infect. Immun. 21:729-737.
27. Han, Y., and J. E. Cutler. 1995. Antibody response that protects against disseminated candidiasis. Infect. Immun. 63:2714-2719.
28. Hashigucci, K., H. Ogawa, T. Ishidate, R. Yamashita, H. Kamiya, K. Watanabe, N. Hattori, T. Sato, Y. Suzuki, T. Nagamine, C. Aizawa, S. Tamura, T. Kurata, and A. Oya. 1996. Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin. Vaccine 14:113-119.
29. Hathaway, L. J., C. D. Partidos, P. Vohra, and M. W. Steward. 1995. Induction of systemic immune responses to measles virus synthetic peptides administered intranasally. Vaccine 13:1495-1500.
30. Ishiguro, A., M. Homma, T. Sukai, K. Higashide, S. Torii, and K. Tanaka. 1992. Immunoblotting analysis of sera from patients with Candidal vaginitis and healthy females. J. Med. Vet. Mycol. 30:281-292.
31. Katz, J. M., X. Lu, S. A. Young, and J. C. Galphin. 1997. Adjuvant activity of the heat-labile enterotoxin from enterotoxigenic Escherichia coli for oral administration of inactivated influenza virus vaccine. J. Infect. Dis. 175:352-363.
32. Katz, J. M., X. Lu, J. C. Galphin, and J. D. Clements. 1196. Heat-labile enterotoxin from E. coli as an adjuvant for oral influenza vaccination, p. 292-297. In L. E. Brown, A. W. Hampson, and R. G. Webster (ed.), Options for the control of influenza, vol. III. Elsevier Science Publishing. Inc., New York, N.Y.
33. Keller, B. I., P. D. Simmons, and L. Ivanyl. 1990. Identification of immunodominant antigens of Candida albicans in patients with superficial candidosis. Clin. Immunol. Immunopathol. 54:347-353.
34. Lee, C. K., R. Weltzin, W. D. Thomas, Jr., H. Kleanthous, T. H. Ermak, G. Soman, J. E. Hill, S. K. Ackerman, and T. P. Monath. 1995. Oral immunization with recombinant Helicobacter pylori urease induces secretory IgA antibodies and protects mice from challenge with Helicobacter felis. J. Infect. Dis. 172:161-172.
35. Levy, R., E. Segal, and L. Barr-Nea. 1985. Systemic candidiasis in mice immunized with Candida albicans ribosomes. Mycopathologia 91:17-22.
36. Lycke, N., T. Tsuji, and J. Holmgren. 1992. The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity. Eur. J. Immunol. 22:2277-2281.
37. Mason, H. S., J. M. Ball, J. J. Shi. X. Jiang, M. K. Estes, and C. J. Arntzen. 1996. Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice. Proc. Natl. Acad. Sci. USA 93: 5335-5340.
38. Matthews, R. C., J. P. Burnie, D. Howat, T. Rowland, and F. Walton, 1991. Autoantibody to heat-shock protein 90 can mediate protection against systemic candidosis. Immunology 74:20-24.
39. Mencacci, A., A. Torosantucci, R. Spaccapelo, L. Romani, F. Bistoni, and A. Cassone. 1994. A mannoprotein constituent of Candida albicans that elicits different levels of delayed-type hypersensitivity, cytokine production, and anticandidal protection in mice. Infect. Immun. 62:5353-5360.
40. Mourad, S., and L. Friedman. 1961. Active immunization of mice against Candida albicans. Proc. Soc. Exp. Biol. Med. 106:570-572.
41. O'Neal, C. M., J. D. Clements, M. K. Estes, and M. E. Conner. 1998. Rotavirus 2/6 viruslike particles administered intranasally with cholera toxin, Escherichia coli heat-labile toxin (LT), and LT-R192G induce protection from rotavirus challenge. J. Virol. 72:3390-3393.
42. Reiss, E., S. H. Stone, and H. F. Hasenclever. 1974. Serological and cellular immune activity of peptidoglucomannan fractions of Candida albicans cell walls. Infect. Immun. 9:881-890.
43. Restrepo-Moreno, A., and J. D. Schneidau, Jr. 1967. Nature of the skin-reactive principle in culture filtrates prepared from Paracoccidioides brasiliensis. J. Bacteriol. 93:1741-1748.
44. Romani, L., A. Mencacci, E. Cenci, P. Mosci, G. Vitellozzi, U. Grohmann, P. Puccetti, and F. Bistoni. 1992. Course of primary candidiasis in T cell-depleted mice infected with attenuated variant cells. J. Infect. Dis. 166:1384-1392.
45. Segal, E., S. Nussbaum, and L. Barr-Nea. 1985. Protection against systemic infections with various Candida species elicited by vaccination with Candida albicans ribosomes. Sabouraudia 23:275-285.
46. Sieck, T. G., M. A. Moors, H. R. Buckley, and K. J. Blank. 1993. Protection against murine disseminated candidiasis mediated by a Candida albicans-specific T-cell line. Infect. Immun. 61:3540-3543.
47. Soles, P., L. Y. Lim, and D. B. Louria. 1967. Active immunity in experimental candidiasis in mice. Sabouraudia 5:315-322.
48. Staats, H. F., W. G. Nichols, and T. J. Palker. 1996. Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A). J. Immunol. 157:462-472.
49. Tavares, D., P. Ferreira, M. Vilanova, A. Videira, and M. Arala-Chaves. 1995. Immunoprotection against systemic candidiasis in mice. Int. Immunol. 7:785-796.
50. Weltzin, R., H. Kleanthous, F. Guirakhoo, T. P. Monath, and C. K. Lee. 1997. Novel intranasal immunization techniques for antibody induction and protection of mice against gastric Helicobacter felis infection. Vaccine 15: 370-376.
51. Wu, H. Y., M. H. Nahm, Y. Guo, M. W. Russell, and D. E. Briles. 1997. Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae. J. Infect. Dis. 175:839-846.
52. Xu-Amano, J., R. J. Jackson, K. Fujihashi, H. Kiyono, H. F. Staats, and J. R. McGhee. 1994. Helper Th1 and Th2 cell responses following mucosal or systemic immunization with cholera toxin. Vaccine 12:903-911.
53. Xu-Amano, J., H. Kiyono, R. J. Jackson, H. F. Staats, K. Fujihashi, P. D. Burrows, C. O. Elson, S. Pillai, and J. R. McGhee. 1993. Helper T cell subsets for immunoglobulin A responses: oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosal associated tissues. J. Exp. Med. 178:1309-1320.
54. Yamamoto, M., J. L. Vancott, N. Okahashi, M. Marinaro, H. Kiyono, K. Fujihashi, R. J. Jackson, S. N. Chatfield, H. Bluethmann, and J. R. McGhee. 1996. The role of Th1 and Th2 cells for mucosal IgA responses. Ann. N. Y. Acad. Sci. 778:64-71.